In vitro activity of resorcinarene-chlorambucil conjugates for therapy in human chronic myelogenous leukemia cells

Drug Dev Ind Pharm. 2019 Apr;45(4):683-688. doi: 10.1080/03639045.2019.1569036. Epub 2019 Jan 28.

Abstract

A possible way of improving the activity and selectivity profile of antitumor agents is to design drug carrier systems employing soluble macromolecules. Thus, four resorcinarene-PAMAM-dendrimer conjugates of chlorambucil with different groups in the lower part of the macrocycle and different length dendritic arms showed a good stability of the chemical link between drug and spacer. Evaluation of the cytotoxicity of the resorcinarene-PAMAM-dendrimer-chlorambucil conjugate employing a sulforhodamine B (SRB) assay in K-562 (human chronic myelogenous leukemia cells) demonstrated that the conjugate was more potent as an antiproliferative agent than chlorambucil.

Keywords: Leukemia cancer; chlorambucil; conjugates; dendrimers; resorcinarene.

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Calixarenes / chemistry*
  • Chlorambucil / administration & dosage*
  • Dendrimers / chemistry
  • Drug Carriers / chemistry*
  • Drug Screening Assays, Antitumor
  • Humans
  • K562 Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Phenylalanine / analogs & derivatives*
  • Phenylalanine / chemistry

Substances

  • Antineoplastic Agents
  • Dendrimers
  • Drug Carriers
  • PAMAM Starburst
  • resorcinarene
  • Calixarenes
  • Chlorambucil
  • Phenylalanine